Trial Condition(s):

Wet Macular Degeneration

Aflibercept (Eylea) in roUtine clinical practice in patientS with wet age-related macular degeneration in Italy (PERSEUS–IT)

Bayer Identifier:

17634

ClinicalTrials.gov Identifier:

NCT02289924

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The main objectives of this non-interventional cohort field study are to evaluate effectiveness of Eylea and to describe follow-up as well as treatment patterns in patients with wAMD (wet age-related macular degeneration) in routine clinical practice in Italy for a study population of “naïve” patients

Inclusion Criteria
- “Naïve” patients with wet AMD(age-related macular degeneration) treated with Eylea (in accordance with the local Summary of Product Characteristics, SPC).
Exclusion Criteria
- Exclusion criteria as listed in the local SPC. Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.
 - Any concomitant therapy with another agent to treat wet AMD in the study eye.
 - Any prior or concomitant therapy with another drug for wAMD.

Trial Summary

Enrollment Goal
912
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Italy

Status
Completed
 

Trial Design